Palvella Therapeutics (PVLA) Total Liabilities (2013 - 2026)
Palvella Therapeutics (PVLA) posted quarterly Total Liabilities of $31.4 million for Q1 2026, up 31.78% year-over-year from $23.9 million in Q1 2025, and little changed quarter-over-quarter from $31.6 million in Q4 2025.
Palvella Therapeutics (PVLA) Total Liabilities (2013 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Total Liabilities for 14 consecutive years, with $31.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 31.78% year-over-year to $31.4 million; the TTM figure through Mar 2026 stood at $31.4 million (up 31.78% YoY), while the FY2025 annual figure was $31.6 million, up 23.21% from the prior year.
- Total Liabilities steadied at $31.4 million in Q1 2026 per PVLA's latest filing, from $31.6 million in the prior quarter.
- Across five years, Total Liabilities topped out at $83.7 million in Q1 2022 and bottomed at $11.4 million in Q4 2023.
- Historically, Total Liabilities has averaged $40.0 million across 5 years, with a median of $29.5 million in 2024.
- Annual changes were most pronounced in 2023 — Total Liabilities sank 83.08% — and 2024, when it surged 124.25%.
- Palvella Therapeutics' Total Liabilities stood at $67.6 million in 2022, then tumbled by 83.08% to $11.4 million in 2023, then soared by 124.25% to $25.6 million in 2024, then grew by 23.21% to $31.6 million in 2025, then dropped by 0.41% to $31.4 million in 2026.
- Business Quant data shows PVLA's Total Liabilities at $31.4 million in Q1 2026, $31.6 million in Q4 2025, and $28.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Palvella Therapeutics | 2.25 Bn | 1.93 Bn | - | 36.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 36.64 Mn |
| Mar 31, 2026 | 31.45 Mn |
| Dec 31, 2025 | 31.58 Mn |
| Sep 30, 2025 | 28.26 Mn |
| Jun 30, 2025 | 25.97 Mn |
| Mar 31, 2025 | 23.86 Mn |
| Dec 31, 2024 | 25.63 Mn |
| Sep 30, 2024 | 20.52 Mn |
| Jun 30, 2024 | 25.05 Mn |
| Mar 31, 2024 | 29.50 Mn |
| Dec 31, 2023 | 11.43 Mn |
| Sep 30, 2023 | 28.87 Mn |
| Jun 30, 2023 | 47.05 Mn |
| Mar 31, 2023 | 66.80 Mn |
| Dec 31, 2022 | 67.56 Mn |
| Sep 30, 2022 | 63.40 Mn |
| Jun 30, 2022 | 69.94 Mn |
| Mar 31, 2022 | 83.67 Mn |
| Dec 31, 2021 | 102.81 Mn |
| Sep 30, 2021 | 110.33 Mn |